[{"orgOrder":0,"company":"Cellf BIO","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"Autologous Bioengineered Internal Anal Sphincter","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Cellf BIO","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Cellf BIO \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cellf BIO \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by Cellf BIO

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          RDD 2025
                          Not Confirmed
                          RDD 2025
                          Not Confirmed

                          Lead Product(s) : Autologous Bioengineered Internal Anal Sphincter

                          Therapeutic Area : Gastroenterology

                          Study Phase : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : The trial will assess the safety of the treatment and the potential initial efficacy of the BioSphincter (Autologous Bioengineered Internal Anal Sphincter) in reducing the number of incontinence episodes in patients with severe fecal incontinence.

                          Product Name : BioSphincter

                          Product Type : Other Large Molecule

                          Upfront Cash : Inapplicable

                          May 01, 2023

                          Lead Product(s) : Autologous Bioengineered Internal Anal Sphincter

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank